Family physician involvement in cancer care and lung cancer patient emotional distress and quality of life.

PURPOSE: This study aims to describe emotional distress and quality of life (QoL) of patients at different phases of their lung cancer and the association with their family physician (FP) involvement. METHODS: A prospective study on patients with lung cancer was conducted in three regions of Quebec, Canada. Patients completed, at baseline, several validated questionnaires regarding their psychosocial characteristics and their perceived level of FP involvement. Emotional distress [profile of mood states (POMS)] and QoL [European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30)] were reassessed every 3-6 months, whether patients had metastasis or not, up to 18 months. Results were regrouped according to cancer phase. Mixed models with repeated measurements were performed to identify variation in distress and QoL. RESULTS: In this cohort of 395 patients, distress was low at diagnosis (0.79 ± 0.7 on a 0-4 scale), raising to 1.36 ± 0.8 at the advance phase (p < 0.0001). Patient's global QoL scores significantly decreased from the diagnosis to the advance phase (from 66 to 45 on a 0-100 scale; p < 0.0001). At all phases of cancer, FP involvement was significantly associated with patients' distress (p = 0.0004) and their global perception of QoL (p = 0.0080). These associations remained statistically significant even after controlling for age, gender, and presence of metastases. CONCLUSIONS: This study provides new knowledge on patients' emotional distress and QoL with cancer evolution and, particularly, their association with FP involvement. Other studies should be conducted to further explore FP role in cancer supportive care.

Le coeur inquiet du christianisme

(Résumé du numéro) Prophéties et visions du futur Notre époque se méfie des prophètes, mais fait confiance aux astrologues, devins et autres voyantes... Y compris dans les plus hautes sphères du pouvoir! Ce surgissement de l'irrationnel dans une société fière de sa "science" laisse perplexe. De telles croyances, dont le caractère païen est parfois souligné, entretiennent dans l'esprit du public une confusion fâcheuse entre prophétie et prédiction. Le prophétisme s'en trouve dévalorisé, alors qu'il a joué à certains moments un rôle décisif dans l'histoire de l'humanité. "L'avez-vous remarqué?", écrivait il y a quelques années Bruno Chenu, "À l'heure actuelle, le thème du prophétisme semble s'être évanoui du paysage, tant social qu'ecclésial. Il n'y a plus grand monde pour se risquer à une interpellation forte, à une mise en cause radicale, à une proposition dérangeante. [...] Nous sommes à l'âge des croyances molles. N'est-il pas grand temps de retrouver, collectivement et personnellement, l'inspiration prophétique?" (1). Le prophète est une figure centrale des religions monothéistes. Il porte la sagesse du message divin que les hommes ne savent pas discerner. Donc, il dérange. Et si sa parole est écoutée, voire sollicitée, dans les périodes d'incertitudes, il devient gênant dès lors que le pouvoir - religieux ou politique - pense avoir repris en main les destinées de la communauté. "L'avenir n'est à personne, sire, l'avenir est à Dieu" rappelle, trop tard!, Victor Hugo à Napoléon 1er. Il est vrai que la condamnation des prophètes est souvent consécutive à une catastrophe déclenchée par de "faux" prophètes. La difficulté à identifier la véritable prophétie a entraîné à plusieurs reprises l'annonce de l'extinction du prophétisme, par les sages juifs au deuxième siècle avant notre ère, ou lorsque le christianisme devient la religion officielle de l'Empire romain. À chaque fois, le prophétisme est réapparu, comme si la religion ne pouvait en faire l'économie. C'est l'une des leçons qui ressort le plus clairement du dossier que nous consacrons au couple tumultueux que constituent prophètes et visions du futur. Le prophète porte aussi les espoirs de l'humanité. Un monde sans prophètes serait-il un monde sans espérance?

Emerging pharmacotherapies for alcohol dependence: a systematic review focusing on reduction in consumption.

BACKGROUND: European Medicines Agency guidelines recognize two different treatment goals for alcohol dependence: abstinence and reduction in alcohol consumption. All currently approved agents are indicated for abstinence. This systematic review aimed to identify drugs in development for alcohol dependence treatment and to establish, based upon trial design, if any are seeking market authorization for reduction in consumption. METHODS: We searched PubMed and Embase (December 2001-November 2011) to identify agents in development for alcohol dependence treatment. Additional studies were identified by searching ClinicalTrials.gov and the R&D Insight and Clinical Trials Insight databases. Studies in which the primary focus was treatment of comorbidity, or n≤20, were excluded. Studies were then classified as 'abstinence' if they: described a detoxification/alcohol withdrawal period; enrolled patients who had undergone detoxification previously; or presented relapse/abstinence rates as the primary outcome. Studies in patients actively drinking at baseline were classified as 'reduction in consumption'. RESULTS: Of 602 abstracts identified, 45 full-text articles were eligible. Five monotherapies were in development for alcohol dependence treatment: topiramate, fluvoxamine, aripiprazole, flupenthixol and nalmefene. Nalmefene was the only agent whose sponsor was clearly seeking definitive approval for reduction in consumption. Development status was unclear for topiramate, fluvoxamine, aripiprazole and flupenthixol. Fifteen agents were examined in published exploratory investigator-initiated trials; the majority focused on abstinence. Ongoing (unpublished) trials tended to focus on reduction in consumption. CONCLUSIONS: While published studies generally focused on abstinence, ongoing trials focused on reduction in consumption, suggesting a change in emphasis in the approach to treating alcohol dependence.

Family physician involvement in cancer care follow-up: the experience of a cohort of patients with lung cancer.

PURPOSE There has been little research describing the involvement of family physicians in the follow up of patients with cancer especially during the primary treatment phase We undertook a prospective longitudinal study of patients with lung cancer to assess their family physician s involvement in their follow up at the different phases of cancer METHODS In 5 hospitals in the province of Quebec Canada patients with a recent diagnosis of lung cancer were surveyed every 3 to 6 months whether they had metastasis or not, for a maximum of 18 months to assess aspects of their family physician s involvement in cancer care RESULTS Of the 395 participating patients 92% had a regular family physician but only 60% had been referred to a specialist by him/her or a colleague for the diagnosis of their lung cancer A majority of patients identified the oncology team or oncologists as mainly responsible for their cancer care throughout their cancer journey except at the advanced phase where a majority attributed this role to their family physician At baseline only 16% of patients perceived a shared care pattern between their family physician and oncologists but this pro portion increased with cancer progression Most patients would have liked their family physician to be more involved in all aspects of cancer care CONCLUSIONS Although patients perceive that the oncology team is the main party responsible for the follow up of their lung cancer they also wish their family physicians to be involved Better communication and collaboration between family physicians and the oncology team are needed to facilitate shared care in cancer follow up

Le « milieu » homosexuel suisse durant la Seconde Guerre mondiale

Cette contribution s'intéresse à l'existence de lieux de sociabilité helvétiques entre hommes qualifiés comme étant homosexuels ou encore homoérotes selon le point de vue militant. Dans un pays resté neutre au cours de la Seconde Guerre mondiale et replié sur lui-même par « Défense nationale », fédéral depuis 1848 en unifiant trois cultures linguistiques, la capitale économique, Zürich, ressort sans conteste comme étant celle de l'homosexualité. Aussi cet article expose-t-il les conditions pénales expliquant l'existence dans cette ville de l'unique association homosexuelle qui va perdurer au-delà du conflit mondial. Il analyse aussi son mode de fonctionnement et revendicatif excluant progressivement les femmes de son sein. Toutefois, le monde associatif ne représente que la surface des événements, et cette étude s'attache à montrer les fortes différences existant selon les régions : la Zürich de la guerre ne s'est pas substituée au Berlin d'avant 1933, et les contrées latines, bien que profondément influencées par le code Napoléon, n'apparaissent pas comme des enclaves de liberté. Tolérance sociale relative et discrétion volontaire des intéressés, tels sont les mécanismes de cette histoire.

Patient, primary care physician and specialist expectations of primary care physician involvement in cancer care.

BACKGROUND: In Canada, many health authorities recommend that primary care physicians (PCP) stay involved throughout their patients' cancer journey to increase continuity of care. Few studies have focused on patient and physician expectations regarding PCP involvement in cancer care. OBJECTIVE: To compare lung cancer patient, PCP and specialist expectations regarding PCP involvement in coordination of care, emotional support, information transmission and symptom relief at the different phases of cancer. DESIGN: Canadian survey of lung cancer patients, PCPs and cancer specialists PARTICIPANTS: A total of 395 patients completed questionnaires on their expectations regarding their PCP participation in several aspects of care, at different phases of their cancer. Also, 45 specialists and 232 community-based PCP involved in these patients' care responded to a mail survey on the same aspects of cancer care. RESULTS: Most specialists did not expect participation of the PCP in coordination of care in the diagnosis and treatment phases (65% and 78% respectively), in contrast with patients (83% and 85%) and PCPs (80% and 59%) (p < 0.0001). At these same phases, the best agreement among the 3 groups was around PCP role in emotional support: 84% and more of all groups had this expectation. PCP participation in symptom relief was another shared expectation, but more unanimously at the treatment phase (p = 0.85). In the advanced phase, most specialists expect a major role of PCP in all aspects of care (from 81% to 97%). Patients and PCP agree with them mainly for emotional support and information transmission. CONCLUSION: Lung cancer patient, PCP and specialist expectations regarding PCP role differ with the phase of cancer and the specific aspect of cancer care. There is a need to reach a better agreement among them and to better define PCP role, in order to achieve more collaborative and integrated cancer care.

The economic burden of alcohol dependence in europe.

AIMS: To determine the economic burden pertaining to alcohol dependence in Europe. METHODS: Database searching was combined with grey literature searching to identify costs and resource use in Europe relating to alcohol dependence as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) or the World Health Organisation's International Classification of Diseases (ICD-10). Searches combined MeSH headings for both economic terms and terms pertaining to alcohol dependence. Relevant outcomes included direct healthcare costs and indirect societal costs. Main resource use outcomes included hospitalization and drug costs. RESULTS: Compared with the number of studies of the burden of alcohol use disorders in general, relatively few focussed specifically on alcohol dependence. Twenty-two studies of variable quality were eligible for inclusion. The direct costs of alcohol dependence in Europe were substantial, the treatment costs for a single alcohol-dependent patient lying within the range euro1591-euro7702 per hospitalization and the annual total direct costs accounting for 0.04-0.31% of an individual country's gross domestic product (GDP). These costs were driven primarily by hospitalization; in contrast, the annual drug costs for alcohol dependence were low. The indirect costs were more substantial than the direct costs, accounting for up to 0.64% of GDP per country annually. Alcohol dependence may be more costly in terms of health costs per patient than alcohol abuse. CONCLUSIONS: This review confirms that alcohol dependence represents a significant burden for European healthcare systems and society. Difficulties in comparing across cost-of-illness studies in this disease area, however, prevent specific estimation of the economic burden.